Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit

BACKGROUND: Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for treating patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). In this review, we discuss recent developments in the optimization of RR-DTC treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirth, Lori J, Durante, Cosimo, Topliss, Duncan J, Winquist, Eric, Robenshtok, Eyal, Iwasaki, Hiroyuki, Luster, Markus, Elisei, Rossella, Leboulleux, Sophie, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256022/
https://www.ncbi.nlm.nih.gov/pubmed/35482606
http://dx.doi.org/10.1093/oncolo/oyac065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256022/
https://www.ncbi.nlm.nih.gov/pubmed/35482606
http://dx.doi.org/10.1093/oncolo/oyac065

Ejemplares similares